Daewon Pharmaceutical 19%↑, biotech stocks strengthen on expectations for Hanmi Pharmaceutical technology exports
Daewon Pharmaceutical shares rose on expectations for an obesity drug 19% higher. Hanmi Pharmaceutical saw expectations for additional technology exports after its Lilly agreement and reports of a raised target price, while some warned of the possibility of the KOSPI 20% decline.
Get free 대원제약 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
South Korean stocks showed mixed trading, with positive news related to biotechnology alongside broad warnings. Some analysts raised the possibility that the KOSPI could fall by 20% and cited a target index of the ten-thousand-won level. Investor sentiment appeared to waver in response to these remarks.29The remarks caused investor sentiment to appear unsettled.
Daewon Pharmaceutical saw its shares rise on expectations for its 2026-06-08 obesity drug, 19% higher. Related disclosures and clinical news reportedly attracted investor attention. During the same period, it showed a trend distinct from other stocks.
Hanmi Pharmaceutical said, along with the company and securities firms, that the possibility of additional technology exports had increased after its agreement with Lilly. Some securities firms raised their target prices to reflect this. The company announced the related information in a disclosure.
Samsung C&T was assessed as having a relatively low share price compared with its earnings despite the rise in its stock price. Accordingly, a securities firm was reported to have raised its target price. An explanation of indicators comparing the share price and earnings was also provided.
T-Robotics received the Čapek Award at an awards ceremony held in China. It was reported that the company’s potential to expand physical AI was recognized as the background to the award. The company was said to have expressed its intention to expand its business in connection with the award.
In this series of developments, the biotechnology sector saw significant price movements by individual stock. Some stocks responded to expectations for specific technology exports, while a sense of caution emerged in other sectors. Investors were reported to have reviewed each company’s disclosures and securities-firm reports.